NewsBenzingaCoya Therapeutics anuncia el reclutamiento completo de los 120 participantes previstos en el ensayo ALSTARS de fase 2/3 que evalúa COYA 302 para el posible tratamiento de la esclerosis lateral amiotrófica Coya Therapeutics anuncia el reclutamiento completo de los 120 participantes previstos en el ensayo ALSTARS de fase 2/3 que evalúa COYA 302 para el posible tratamiento de la esclerosis lateral amiotrófica Benzinga 2026.10.05 12:03 (GMT+0) Open on Benzinga Other news Here's How Much $1000 Invested In Coeur Mining 5 Years Ago Would Be Worth Today Anthropic Gives 5% of Itself to the Public. Musk Answers by Giving Away SpaceX Shares Standex International Appoints Samantha L. Stoddard As CFO Effective December 1, 2026 U.S. Transportation Secretary Duffy Expected To Announce Certification Of Boeing 737 Max 10 On Tuesday In Washington State Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000... 12 Industrials Stocks Moving In Monday's After-Market Session
U.S. Transportation Secretary Duffy Expected To Announce Certification Of Boeing 737 Max 10 On Tuesday In Washington State
Vivos Therapeutics Closes Its Acquisition Of An 11% Fully Diluted Equity Interest In Sod Sciences And A 50% Undivided Co-Ownership Interest In SOD's Pseudohypoxia Early‑Warning Test, The "Primed Cell For Chronic Disease" Test; Vivos Issued To SOD 12,000...
